Loading…
Loading…
CYDX does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CYDX and 80,000+ other tickers.
See exactly how CYDX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CYDX and 80,000+ other tickers.
CYduct Diagnostics, Inc. operates as a medical instrument enterprise that engineers and commercializes a diverse range of technologies, equipment, and methodologies. These innovations are purposed for the detection, diagnosis, therapeutic intervention, and general management of various health conditions and illnesses. The company's extensive product offerings include specialized breast endoscopy systems, an assortment of camera solutions (such as 3-chip and 1-chip models), and all necessary accessories. They also provide a broad selection of endoscopic instruments, encompassing surgical tools…
Yale Innovation Summit, May 29-30, New Haven, CT. WESTPORT, CT / ACCESSWIRE / May 16, 2024 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct", "CYductDX", or the "Company"), an innovator in precision breast health enabled by non-invasive intraductal platforms, today announced it is pleased to present at the 2024 Yale Innovation Summit, being held from May 29-30 in New Haven, CT.
WESTPORT, CT / ACCESSWIRE / April 2, 2024 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct", or the "Company"), a precision medicine-based women's health company focused on the development of breast cancer risk assessment and diagnostic tools, today announced positive results from its recent research on breast cancer biomarkers. The pilot study, utilizing liquid biopsy samples, met its primary endpoint of measuring specific biomarker concentrations demonstrating a significant correlation to predict breast health, and a clinically meaningful improvement compared to measuring one biomarker alone.
WESTPORT, CT / ACCESSWIRE / October 31, 2023 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct" or the "Company"), CYduct Diagnostics Inc., a leading medical device company committed to revolutionizing women's healthcare, is pleased to announce its wholehearted support for the "Find It Early Act," a critical piece of legislation introduced by Congresswoman Rosa DeLauro (CT-03), Congressman Brian Fitzpatrick (PA-01), and renowned journalist Katie Couric in May of this year. This bill is a significant step forward in enhancing women's healthcare and ensuring access to additional screening and diagnostic testing for those at risk of or with dense breasts.
WESTPORT, CT / ACCESSWIRE / October 19, 2023 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct" or the "Company"), CYduct Diagnostics Inc., a leading medical device company committed to revolutionizing women's healthcare, with a primary focus on breast health and wellness, is highlighting the critical significance of Breast Cancer Awareness Month. At CYduct Diagnostics Inc., we are dedicated to pioneering new testing methods that prioritize clinical integrity, patient privacy, and convenience in the quest for enhanced breast healthcare.
WESTPORT, CT / ACCESSWIRE / August 1, 2023 / CYduct Diagnostics, Inc. (OTCPK:CYDX) ("CYduct" or the "Company"), - CYduct Diagnostics an emerging force in women's breast health would like to recognize the immeasurable impact that Dr. Susan Love, a visionary leader in defining solutions for breast disease had on our company. Dr. Susan Love, who recently passed, had an untiring dedication to advancing medical diagnostics and her invaluable knowledge have left an indelible mark on our organization and the entire healthcare community.